文献速递神经免疫

2024年多发性硬化诊断标准修订对放射学孤立综合征患者的影响

Impact of 2024 Revisions of Multiple Sclerosis Diagnostic Criteria in People With Radiologically Isolated Syndrome.
PubMed 文献 · Neurology · 2026-11-05

这项多中心回顾性研究纳入236例符合2023年RIS标准的成人患者,应用2024年McDonald标准后,67.4%的患者在基线即被重新分类为多发性硬化。随访中42例出现临床事件的患者里,88.1%可提前中位2年被诊断。研究提示新标准使多数RIS患者更早获得MS诊断。

要点

  • 2024标准使67.4%的RIS患者在基线即符合MS诊断。
  • 随访出现临床事件者中88.1%可提前中位2年诊断MS。
  • 基线时96.6%符合空间多发,21.6%符合时间多发。

核心结论

  • 2024年McDonald标准修订使多数既往分类为RIS的患者在出现典型症状前即被诊断为MS。

研究设计与样本

  • 多中心回顾性研究,纳入22家意大利MS三级中心的236例符合2023年Lebrun-Frénay RIS标准的成人患者(平均年龄38.9±11.6岁,70.3%女性,中位随访3.0年)。

主要发现

  • 基线时228例(96.6%)符合空间多发(DIS),51例(21.6%)符合放射学时间多发(DIT),201例有脑脊液数据的患者中152例(75.6%)脑脊液阳性。
  • 基线时2024标准使159/236例(67.4%)RIS患者诊断为MS。
  • 随访中42例出现临床事件,其中88.1%可提前中位2年(IQR 1.0-5.5)被重新分类为MS。
  • 随访期间另有18/236例(7.6%)通过放射学DIT满足诊断标准。

关键数值与推荐

  • 2024标准允许RIS患者在≥2个典型MS区域存在≥1个T2高信号病灶(即DIS),加上MRI时间多发(DIT)、脑脊液阳性或中央静脉征(CVS)阳性时诊断MS。

临床怎么用

  • 对符合RIS标准的患者,可依据2024标准评估DIS、DIT、脑脊液或CVS以早期识别可诊断为MS者。

局限性

  • kappa游离轻链指数数据不完整,MRI采集方案未标准化。
  • 真实世界背景下回顾性CVS评估可忽略(仅5/236例有CVS数据,均阴性)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: The biological onset of multiple sclerosis (MS) precedes its clinical onset by years, as shown by MRI and CSF biomarkers. The 2024 revisions of the McDonald criteria extend, for the first time, MS diagnosis to selected cases of radiologically isolated syndrome (RIS), that is, to people with incidentally discovered CNS lesions suggestive of autoimmune inflammatory demyelination, in the absence of typical symptoms. The aim of this multicenter study was to assess the proportion of patients with RIS reclassified as MS, after applying the 2024 criteria. METHODS: Adult participants (≥18 years) fulfilling the 2023 Lebrun-Frénay RIS criteria were selected from 22 Italian MS tertiary centers. Real-world, registry-based data were retrospectively collected at both baseline and follow-up. Reclassification followed 2024 criteria, allowing a MS diagnosis in RIS cases with ≥1 T2-hyperintense lesion in ≥2 typical MS regions (i.e., dissemination in space [DIS]), plus either MRI evidence of dissemination in time (DIT), CSF positivity, or central vein sign (CVS) positivity. Descriptive statistics were used. RESULTS: Among 236 patients with RIS (mean age 38.9 ± 11.6 years; 70.3% female; median follow-up 3.0 years [interquartile range {IQR}: 1.1-6]), at baseline, 228 (96.6%) fulfilled DIS, 51 (21.6%) fulfilled radiologic DIT, and 152 of 201 individuals with available CSF data were CSF-positive (75.6%). CVS data were available for 5 of 236 individuals; none were CVS-positive. At baseline, the 2024 criteria resulted in a MS diagnosis in 159 of 236 patients with RIS (67.4%). Of 42 patients with RIS experiencing a clinical event during follow-up, 88.1% would have been reclassified as MS a median of 2 years earlier (IQR: 1.0-5.5). During follow-up, 18 of 236 additional participants (7.6%) met the diagnostic criteria through radiologic DIT. DISCUSSION: The introduction of the 2024 criteria results in an earlier diagnosis of MS, before clinical manifestations of focal CNS damage, in most people formerly classified as RIS. Study limitations include incomplete kappa free light chain index data and nonstandardized MRI acquisition protocols; particularly, retrospective CVS assessment was negligible in this real-life context. Future studies including the full spectrum of asymptomatic individuals with MRI abnormalities and available paraclinical diagnostic tools are needed to better define the impact of 2024 revised criteria in this population.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Di Filippo M, Masillo V, Di Sabatino E, et al. Impact of 2024 Revisions of Multiple Sclerosis Diagnostic Criteria in People With Radiologically Isolated Syndrome. Neurology. 2026. PMID: 42987244. doi:10.1212/WNL.0000000000218691

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。